INVA Insider Trading
Insider Ownership Percentage: 1.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Innoviva Share Price & Price History
Current Price: $18.58
Price Change: ▲ Price Increase of +0.13 (0.70%)
As of 01/17/2025 05:00 PM ET
Innoviva Insider Trading History
Innoviva Institutional Trading History
Data available starting January 2016
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Read More on Innoviva
Today's Range
Now: $18.58
52 Week Range
Now: $18.58
Volume
606,495 shs
Average Volume
542,593 shs
Market Capitalization
$1.16 billion
P/E Ratio
26.93
Dividend Yield
N/A
Beta
0.54
Who are the company insiders with the largest holdings of Innoviva?
Who are the major institutional investors of Innoviva?
Which institutional investors are selling Innoviva stock?
In the last quarter, INVA stock was sold by these institutional investors:
- Everence Capital Management Inc.
Which institutional investors are buying Innoviva stock?
In the previous quarter, INVA stock was acquired by institutional investors including:
- CWA Asset Management Group LLC
- Ritholtz Wealth Management
Within the previous year, these company insiders have bought Innoviva stock:
- Alexander J Denner (Major Shareholder)
- Pavel Raifeld (CEO)
Learn More investors buying Innoviva stock.